Asensus Surgical Announces Installation of Senhance Surgical System in the Department of Gynecology at University Hospital TübingenAsensus Surgical Announces Installation of Senhance Surgical System in the Department of Gynecology at University Hospital Tübingen

Asensus Surgical Announces Installation of Senhance Surgical System in the Department of Gynecology at University Hospital Tübingen

3 years ago

This becomes the 6th Senhance Hospital in GermanyRESEARCH TRIANGLE PARK, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc.…

ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022

ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022

3 years ago

PORTLAND, Maine, July 07, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company…

Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated DiseaseImmuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease

3 years ago

MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on…

ACTO Secures $18M Financing to Accelerate Growth and Strengthen Position as #1 Learning Platform in Life SciencesACTO Secures $18M Financing to Accelerate Growth and Strengthen Position as #1 Learning Platform in Life Sciences

ACTO Secures $18M Financing to Accelerate Growth and Strengthen Position as #1 Learning Platform in Life Sciences

3 years ago

ACTO CXO Team (left to right): Kapil Kalra (CCO), John Schultz (CSO), Alison Muller (CMO), Parth Khanna (CEO), Kumar Erramilli…

EVEON announces the launch of the European project INDENEO to develop an innovative delivery system for nose to brain administration of biological and advanced therapy drugs to neonatesEVEON announces the launch of the European project INDENEO to develop an innovative delivery system for nose to brain administration of biological and advanced therapy drugs to neonates

EVEON announces the launch of the European project INDENEO to develop an innovative delivery system for nose to brain administration of biological and advanced therapy drugs to neonates

3 years ago

EVEON, designer and manufacturer of medical devices for the preparation and delivery of drugs, announces the launch of a European…

Calibre Scientific UK Relocates to State-Of-The-Art Facility in the Advanced Manufacturing Park, SheffieldCalibre Scientific UK Relocates to State-Of-The-Art Facility in the Advanced Manufacturing Park, Sheffield

Calibre Scientific UK Relocates to State-Of-The-Art Facility in the Advanced Manufacturing Park, Sheffield

3 years ago

LOS ANGELES, July 07, 2022 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the relocation of three key UK…

Chr. Hansen Holding A/S Interim Report Q3 2021/22Chr. Hansen Holding A/S Interim Report Q3 2021/22

Chr. Hansen Holding A/S Interim Report Q3 2021/22

3 years ago

Company announcement no. 05/2022 July 7, 2022 Solid Q3 in an uncertain macroeconomic environment Statement by CEO Mauricio Graber: “The…

Genespire appoints Dr. Sabah Sallah as Chief Medical OfficerGenespire appoints Dr. Sabah Sallah as Chief Medical Officer

Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

3 years ago

Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins…

Spexis’ CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical modelSpexis’ CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

Spexis’ CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model

3 years ago

ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its…

Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell PhysiologyNicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell Physiology

3 years ago

Press Release Nicox Announces Publication of NCX 470 Results Demonstrating Improvements to Ocular Hemodynamics and Retinal Cell PhysiologyJuly 7, 2022…